Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.
Parua P, Ghosh S, Jana K, Seth A, Debnath B, Kumar Rout S, Kumar Sarangi M, Dash R, Halder J, Kanti Rajwar T, Pradhan D, Kumar Rai V, Dash P, Das C, Kar B, Ghosh G, Rath G.
Parua P, et al. Among authors: seth a.
Curr Pharm Des. 2024 Nov 13. doi: 10.2174/0113816128334441241108050528. Online ahead of print.
Curr Pharm Des. 2024.
PMID: 39543801